Pharmaceutical Big Data Insights


This report offers benchmarks designed to help companies build Big Data strategy and infrastructure. As companies uncover the benefits of harnessing multiple, deep data sources, they allocate resources to enhance and develop their Big Data teams. Based on more than 75 Big Data-driven studies, this report focuses on project budgets, team sizes and specific metrics for prospective studies, retrospective studies and market intelligence initiatives. Use its findings and metrics as your go-to guide for building a diverse Big Data team — one positioned to support varied groups, including medical affairs, business development and market access — and to recognize and overcome critical Big Data challenges

Download Now! speak-to-an-expert

Price $3,495
Publication Date January 2014
Pages 357
Chapters 5
Metrics 500 +
Charts / Graphics 287

Download a Sneak Peek Preview of "Pharmaceutical Big Data Insights" Here

See a full Table of Contents and sample material

Top Reasons to Review This Pharmaceutical Big Data Report

Overcome social media challenges to collect data: Social media poses big challenges to drug and device manufacturers, especially when it comes to reporting unsolicited adverse events.  But life science companies have developed methods to better use social media to address those challenges and gather pharmaceutical big data at the same time.  Learn how top companies use social media channels to gather data, such as competitor product usage, patient and physician sentiment and adverse event information.  Implement the best practices from this report to cultivate social media channels as a means to examine target populations’ behaviors, reactions and expectations.

Establish dedicated teams to capitalize on key initiatives: Sixty-three percent of surveyed companies are planning to build dedicated teams.  How they construct those teams and the level of resources they provide to them will determine much of their success.  Use this report to understand why it’s important to build a diverse team that involves expertise from different functional areas.  Consult the resource allocation benchmarks in this report to staff and fund your teams, as well as individual prospective and retrospective studies.

Expand your strategies to increase study efficiency: This report outlines how companies are utilizing Big Data’s efficiency to shorten timelines and decrease budgets of prospective and retrospective studies.  Medical Affairs, Clinical Development and HEOR teams will benefit by the strategies outlined in this report highlighting which data tools to focus on and how to achieve more accurate study results.  Utilizing these strategies during these projects will lead to cost-effective timelines, more accurate study results and an overall stronger drug value proposition.

You may also be interested in our market access library as well as individual market access research reports.

Key Questions This Study Answers about Pharmaceutical Big Data

  1. How can Big Data improve drug and device companies’ initiatives?
  2. How can pharmaceutical and medical device companies measure ROI for Big Data initiatives?
  3. How should drug and device companies allocate resources to pharmaceutical Big Data teams and studies?
  4. What are the best practices for structuring Big Data teams and organizing their initiatives?
  5. Why should companies implement centralized/dedicated teams?
  6. Which organizational functions are leading contributors to pharmaceutical Big Data strategies within the life sciences industry?
  7. Why should pharmaceutical and medical device companies involve multiple functions in Big Data activities?
  8. Which tasks and activities do life science companies most commonly outsource to Big Data vendors?
  9. What information should companies gather from social media and other Big Data sources?
  10. What can life sciences companies gain from using social media channels?
  11. What challenges do drug and device companies encounter when using social media for data gathering?